nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—MAOA—attention deficit hyperactivity disorder	0.408	0.512	CbGaD
Naratriptan—HTR1B—attention deficit hyperactivity disorder	0.389	0.488	CbGaD
Naratriptan—MAOA—locus ceruleus—attention deficit hyperactivity disorder	0.011	0.222	CbGeAlD
Naratriptan—HTR1F—forebrain—attention deficit hyperactivity disorder	0.00451	0.0911	CbGeAlD
Naratriptan—HTR1F—nervous system—attention deficit hyperactivity disorder	0.00245	0.0494	CbGeAlD
Naratriptan—HTR1F—central nervous system—attention deficit hyperactivity disorder	0.00236	0.0476	CbGeAlD
Naratriptan—HTR1F—brain—attention deficit hyperactivity disorder	0.00187	0.0378	CbGeAlD
Naratriptan—HTR1B—forebrain—attention deficit hyperactivity disorder	0.00185	0.0373	CbGeAlD
Naratriptan—HTR1D—forebrain—attention deficit hyperactivity disorder	0.00179	0.0361	CbGeAlD
Naratriptan—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00156	0.0316	CbGeAlD
Naratriptan—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.00151	0.0305	CbGeAlD
Naratriptan—HTR1A—forebrain—attention deficit hyperactivity disorder	0.00149	0.0301	CbGeAlD
Naratriptan—MAOA—forebrain—attention deficit hyperactivity disorder	0.00136	0.0275	CbGeAlD
Naratriptan—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.00126	0.0255	CbGeAlD
Naratriptan—HTR1B—midbrain—attention deficit hyperactivity disorder	0.00122	0.0246	CbGeAlD
Naratriptan—Almotriptan—MAOA—attention deficit hyperactivity disorder	0.00121	0.192	CrCbGaD
Naratriptan—HTR1D—midbrain—attention deficit hyperactivity disorder	0.00118	0.0239	CbGeAlD
Naratriptan—Sumatriptan—MAOA—attention deficit hyperactivity disorder	0.00116	0.185	CrCbGaD
Naratriptan—MAOA—cardiovascular system—attention deficit hyperactivity disorder	0.00115	0.0233	CbGeAlD
Naratriptan—Almotriptan—HTR1B—attention deficit hyperactivity disorder	0.00115	0.184	CrCbGaD
Naratriptan—Sumatriptan—HTR1B—attention deficit hyperactivity disorder	0.00111	0.177	CrCbGaD
Naratriptan—HTR1B—nervous system—attention deficit hyperactivity disorder	0.001	0.0203	CbGeAlD
Naratriptan—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000984	0.0199	CbGeAlD
Naratriptan—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000971	0.0196	CbGeAlD
Naratriptan—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000965	0.0195	CbGeAlD
Naratriptan—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000935	0.0189	CbGeAlD
Naratriptan—MAOA—midbrain—attention deficit hyperactivity disorder	0.000899	0.0182	CbGeAlD
Naratriptan—Eletriptan—HTR1B—attention deficit hyperactivity disorder	0.000897	0.143	CrCbGaD
Naratriptan—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000809	0.0163	CbGeAlD
Naratriptan—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000779	0.0157	CbGeAlD
Naratriptan—HTR1B—brain—attention deficit hyperactivity disorder	0.000766	0.0155	CbGeAlD
Naratriptan—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000761	0.0154	CbGeAlD
Naratriptan—Sumatriptan—DRD2—attention deficit hyperactivity disorder	0.000745	0.119	CrCbGaD
Naratriptan—HTR1D—brain—attention deficit hyperactivity disorder	0.000742	0.015	CbGeAlD
Naratriptan—MAOA—nervous system—attention deficit hyperactivity disorder	0.000739	0.0149	CbGeAlD
Naratriptan—MAOA—central nervous system—attention deficit hyperactivity disorder	0.000712	0.0144	CbGeAlD
Naratriptan—MAOA—cerebellum—attention deficit hyperactivity disorder	0.000696	0.0141	CbGeAlD
Naratriptan—HTR1A—brain—attention deficit hyperactivity disorder	0.000619	0.0125	CbGeAlD
Naratriptan—MAOA—brain—attention deficit hyperactivity disorder	0.000565	0.0114	CbGeAlD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000164	0.00112	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000164	0.00112	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000163	0.00111	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000163	0.00111	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000163	0.00111	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000162	0.00111	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000161	0.0011	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00016	0.00109	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000159	0.00108	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000158	0.00108	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000158	0.00108	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000157	0.00107	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000157	0.00107	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000156	0.00106	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000155	0.00106	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000154	0.00105	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000154	0.00105	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000153	0.00104	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000153	0.00104	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000153	0.00104	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000152	0.00103	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000151	0.00103	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000151	0.00103	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000151	0.00103	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00015	0.00102	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00015	0.00102	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000148	0.00101	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000148	0.00101	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000147	0.001	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000147	0.000999	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000146	0.000998	CbGpPWpGaD
Naratriptan—MAOA—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000146	0.000997	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000146	0.000995	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000144	0.00098	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000142	0.000968	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000141	0.000961	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000141	0.00096	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00014	0.000956	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000139	0.000949	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000138	0.000937	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000137	0.000936	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000136	0.000929	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000136	0.000929	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000134	0.00091	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000133	0.000909	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000133	0.000906	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000132	0.000899	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000131	0.000893	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000131	0.000891	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00013	0.000884	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00013	0.000884	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000129	0.000881	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000129	0.000878	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000128	0.000873	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000128	0.000872	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000128	0.00087	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000128	0.00087	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000127	0.000866	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000125	0.000855	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000125	0.000852	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000125	0.000852	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000124	0.000844	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.000829	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.00012	0.000819	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000119	0.000813	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000119	0.000808	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000118	0.000805	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000117	0.000796	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000117	0.000796	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000115	0.000783	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000113	0.00077	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000113	0.000769	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000112	0.000763	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000112	0.000761	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000112	0.00076	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000109	0.000745	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000109	0.000742	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000107	0.000731	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000106	0.000724	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000104	0.000709	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000104	0.000709	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000104	0.000708	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000104	0.000707	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000104	0.000707	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000102	0.000698	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000102	0.000695	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000102	0.000693	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000102	0.000692	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000101	0.000685	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	9.95e-05	0.000678	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—COMT—attention deficit hyperactivity disorder	9.94e-05	0.000677	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	9.88e-05	0.000673	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	9.86e-05	0.000672	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.84e-05	0.000671	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	9.84e-05	0.000671	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.76e-05	0.000665	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.76e-05	0.000665	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	9.68e-05	0.000659	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	9.67e-05	0.000659	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.65e-05	0.000658	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.56e-05	0.000651	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.55e-05	0.000651	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.55e-05	0.000651	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.53e-05	0.000649	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	9.45e-05	0.000644	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.45e-05	0.000644	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	9.26e-05	0.000631	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	9.17e-05	0.000625	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	9.09e-05	0.000619	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	8.96e-05	0.00061	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	8.92e-05	0.000607	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.9e-05	0.000607	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	8.9e-05	0.000606	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	8.88e-05	0.000605	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	8.73e-05	0.000595	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	8.73e-05	0.000595	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	8.62e-05	0.000587	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	8.57e-05	0.000584	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	8.5e-05	0.000579	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	8.36e-05	0.00057	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	8.33e-05	0.000567	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.33e-05	0.000567	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	8.32e-05	0.000567	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	8.19e-05	0.000558	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	8.07e-05	0.00055	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	8.03e-05	0.000547	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	7.93e-05	0.00054	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.93e-05	0.00054	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	7.83e-05	0.000533	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.77e-05	0.000529	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.74e-05	0.000527	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.5e-05	0.000511	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	7.37e-05	0.000502	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	7.29e-05	0.000497	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.28e-05	0.000496	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.28e-05	0.000496	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	7.22e-05	0.000492	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7.2e-05	0.00049	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	7.07e-05	0.000481	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.05e-05	0.000481	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	6.78e-05	0.000462	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.78e-05	0.000462	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.64e-05	0.000452	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.55e-05	0.000447	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.5e-05	0.000443	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.42e-05	0.000437	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.37e-05	0.000434	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.34e-05	0.000432	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	6.31e-05	0.00043	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.24e-05	0.000425	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.23e-05	0.000425	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.05e-05	0.000412	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.98e-05	0.000408	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.86e-05	0.0004	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	5.77e-05	0.000393	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.74e-05	0.000391	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.73e-05	0.00039	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.7e-05	0.000388	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.68e-05	0.000387	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.63e-05	0.000383	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.59e-05	0.000381	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.58e-05	0.00038	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.58e-05	0.00038	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.56e-05	0.000379	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.51e-05	0.000376	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.48e-05	0.000373	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.47e-05	0.000373	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.47e-05	0.000372	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.4e-05	0.000368	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.38e-05	0.000367	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.36e-05	0.000365	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.33e-05	0.000363	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.29e-05	0.000361	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.21e-05	0.000355	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.16e-05	0.000351	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.14e-05	0.00035	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.11e-05	0.000348	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.07e-05	0.000345	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.05e-05	0.000344	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.03e-05	0.000343	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.01e-05	0.000341	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.96e-05	0.000338	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.95e-05	0.000337	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.92e-05	0.000335	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.9e-05	0.000334	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.89e-05	0.000333	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.76e-05	0.000325	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.75e-05	0.000324	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.71e-05	0.000321	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.68e-05	0.000319	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.66e-05	0.000318	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.63e-05	0.000315	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.57e-05	0.000311	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.37e-05	0.000298	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.31e-05	0.000294	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.27e-05	0.000291	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.25e-05	0.00029	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.24e-05	0.000289	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.17e-05	0.000284	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.16e-05	0.000284	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—TPH2—attention deficit hyperactivity disorder	4.13e-05	0.000281	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.13e-05	0.000281	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.11e-05	0.00028	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.09e-05	0.000278	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—DPYD—attention deficit hyperactivity disorder	4.06e-05	0.000277	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.97e-05	0.000271	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.87e-05	0.000264	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.85e-05	0.000262	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.83e-05	0.000261	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.79e-05	0.000258	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.78e-05	0.000258	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.78e-05	0.000257	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.73e-05	0.000254	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.6e-05	0.000245	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.52e-05	0.00024	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.48e-05	0.000237	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.38e-05	0.000231	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.3e-05	0.000225	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.27e-05	0.000223	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.2e-05	0.000218	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.15e-05	0.000214	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.14e-05	0.000214	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.08e-05	0.00021	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.05e-05	0.000208	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.02e-05	0.000206	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.99e-05	0.000204	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.98e-05	0.000203	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.96e-05	0.000202	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.93e-05	0.0002	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.9e-05	0.000197	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.89e-05	0.000197	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.76e-05	0.000188	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.7e-05	0.000184	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.68e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.52e-05	0.000172	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—COMT—attention deficit hyperactivity disorder	2.5e-05	0.00017	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.44e-05	0.000166	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.35e-05	0.00016	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.27e-05	0.000155	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.23e-05	0.000152	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.21e-05	0.00015	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.06e-05	0.00014	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.93e-05	0.000131	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.89e-05	0.000129	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.6e-05	0.000109	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.44e-05	9.81e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—EP300—attention deficit hyperactivity disorder	1.07e-05	7.31e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.02e-05	6.97e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1e-05	6.82e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.63e-06	5.2e-05	CbGpPWpGaD
